Test Price
2,800 AED✅ Home Collection Available
C1QA Gene C1q Deficiency Genetic Test in UAE — 2,800 AED | Molecular Diagnosis by NGS
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing (NGS) with full coverage of coding regions and splice-site junctions of the C1QA gene.
Turnaround Time: 3 to 4 weeks from sample receipt — definitive molecular report with variant interpretation and clinical recommendations.
Premium Logistics: Complimentary VIP Mobile Phlebotomy & temperature-controlled cold-chain home collection. Available daily from 8 AM to 11 PM across all Emirates.
Post-Test Guidance: Telephonic consultation with a Consultant Medical Geneticist to contextualise results within personal and family medical history.
All-Inclusive Price
2,800
AED
No hidden fees — includes genetic counselling, NGS analysis, and clinical report
Test Overview & Methodology
The C1QA Gene C1q Deficiency Genetic Test is a comprehensive next-generation sequencing analysis that screens for pathogenic variants in the C1QA gene, which encodes the A-chain of complement component C1q — a critical initiator of the classical complement pathway. Deficiencies in C1q are strongly associated with systemic lupus erythematosus-like syndromes, recurrent severe infections, and immune complex-mediated dermatological and renal disorders. This test provides definitive molecular confirmation for suspected complement deficiency, enabling precise clinical management and family screening.
Methodology: Next-Generation Sequencing (NGS) using a validated clinical panel that captures all coding exons, intron-exon boundaries, and flanking regions of C1QA. Bioinformatic analysis identifies single-nucleotide variants, small insertions/deletions, and copy-number alterations. All pathogenic findings are confirmed by Sanger sequencing prior to reporting.
| Parameter | Our Test (NGS) | Closest Alternative (Complement Functional Assay) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity — Single-nucleotide resolution | ~70–80% — Indirect functional measurement; cannot identify specific mutations |
| Methodology | NGS with full gene coverage including intron-exon boundaries | CH50 / C1q Antigenic Assay (ELISA) — Phenotypic only |
| Turnaround Time | 3 to 4 Weeks — Definitive molecular report | 5–10 Days — Requires reflex to genetic testing for confirmation |
| Clinical Utility | Enables cascade family screening, genetic counselling, and personalised treatment planning | Limited — Cannot guide family planning or identify carrier status |
Pre-Test Requirements & Specimen Collection Protocol
- Mandatory Pre-Test Genetic Counselling: A certified genetic counselling session is required to document a comprehensive three-generation pedigree chart identifying all family members affected by or suspected of carrying a C1QA gene variant.
- Clinical History Submission: Detailed history — including age of onset, dermatological manifestations, recurrent infections, autoimmune symptoms, and prior complement function test results — must accompany the test requisition.
- Accepted Sample Types: Whole Blood (EDTA tube, 3–5 mL), Extracted DNA (≥200 ng, TE buffer), or Dried Blood Spot on FTA Card. All samples must be collected by a DHA-licensed phlebotomist.
- Medication & Supplement Disclosure: Patients must disclose all current medications and supplements. Immunosuppressive therapies do not alter germline DNA results but should be noted for concurrent phenotypic testing.
- Minors: For patients under 18 years, written informed consent must be obtained from a legal guardian. Pre-test counselling must include discussion of the implications of predictive genetic testing in minors, in alignment with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Physician Insight & Safety Protocols
"A pathogenic variant in the C1QA gene is a clinically actionable finding with profound implications for both the patient and their at-risk relatives. While this NGS test delivers exceptional analytical accuracy, results must always be correlated with clinical phenotype, complement functional assays, and immunological workup by a qualified specialist. No single laboratory test should dictate clinical decisions in isolation — I strongly recommend a post-test consultation with a clinical immunologist or dermatologist to integrate these molecular findings into a comprehensive care plan."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Do Not Discontinue Prescribed Medication Without Consulting Your Physician
This includes corticosteroids, hydroxychloroquine, immunosuppressants, or any complement-targeted therapy. Genetic test results provide diagnostic clarity but are not a substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed If:
- Patient has received a blood transfusion within the past 30 days (may cause donor DNA interference in NGS analysis)
- Patient has undergone allogeneic bone marrow or stem cell transplantation (circulating leukocyte DNA may not represent patient's germline genotype)
- Insufficient or degraded DNA sample — a minimum of 200 ng of high-quality genomic DNA is required
- Unwillingness to provide informed consent for genetic testing as mandated by UAE Federal Decree-Law No. 4 of 2016 on Medical Liability
Emergency Red Flags — Seek Immediate Medical Attention If You Experience:
- Sudden onset of severe facial or periorbital edema (angioedema) with or without respiratory difficulty
- Acute lupus flare symptoms: pleuritic chest pain, oliguria, confusion, or seizures
- Signs of overwhelming sepsis: high fever (>39°C), rigors, hypotension, or altered mental status
- Severe cutaneous ulceration or necrotizing skin lesions — may indicate immune complex-mediated vasculitis requiring urgent immunosuppression
If you experience any of the above, proceed to the nearest emergency department or call 998 for UAE Ambulance Services immediately. Inform the attending physician of your suspected or confirmed C1q deficiency status.
Patient FAQ & Clinical Guidance
1. What exactly does the C1QA Gene C1q Deficiency Genetic Test detect?
This NGS comprehensively sequences the entire coding region and splice-site junctions of the C1QA gene to identify pathogenic single-nucleotide variants, small insertions or deletions, and copy-number alterations that cause C1q deficiency — a rare primary immunodeficiency linked to early-onset systemic lupus erythematosus and recurrent severe infections. Unlike traditional complement functional assays, this DNA-based approach provides a definitive molecular diagnosis, enabling accurate carrier detection and cascade screening of at-risk family members for proactive clinical surveillance.
2. How is the sample collected and when will I receive my results?
A DHA-licensed phlebotomist collects a standard venous blood sample (3–5 mL in EDTA tube) during a complimentary home visit between 8 AM and 11 PM, with cold-chain transport to our ISO-certified genomics laboratory for NGS processing and bioinformatic analysis, delivering a definitive clinical report within 3 to 4 weeks. Alternatively, you may provide pre-extracted DNA or a dried blood spot on an FTA card if sample logistics require flexibility — all collection methods maintain diagnostic sensitivity exceeding 99.9%.
3. What do the results mean for my health and my family members?
A positive result confirms a molecular diagnosis of C1q deficiency, enabling targeted immunological monitoring, early intervention for autoimmune complications, and informed family planning through cascade genetic testing of first-degree relatives who may be asymptomatic carriers. A negative result substantially reduces the likelihood of a primary complement deficiency but must be interpreted alongside functional complement assays and clinical phenotype for a comprehensive immunological assessment.
UAE Regulatory & Data Privacy Adherence
Your Data. Your Rights. Our Commitment.
DNA Labs UAE operates under DHA Facility License No. 1143 and adheres strictly to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes. Patient consent for genetic testing is obtained and documented in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. We never share your data with third parties without explicit written authorization.
ISO 9001:2015 Certified | DHA-Regulated Laboratory | Facility License: 1143
Clinical & Logistical Metadata
| Test Name | C1QA Gene C1q Deficiency Genetic Test (NGS) |
| Price (AED) | 2,800 AED (All-Inclusive) |
| Turnaround Time | 3 to 4 Weeks from sample receipt |
| Sample Type / Matrix | Whole Blood (EDTA, 3–5 mL), Extracted DNA (≥200 ng), or Dried Blood Spot (FTA Card). VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily 8 AM – 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage including intron-exon boundaries; Sanger confirmation of all pathogenic findings. |
| ICD-10-CM Code | D84.1 (Defects in the complement system) |
| LOINC Code | 94222-3 (C1QA gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians